Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

80.28 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Wednesday Morning Whirlwind
Some of the bigger companies reporting prior to the opening bell today. 
Via Talk Markets
Banned Merger
Today stock markets are in disarray after the full horror of Beijing's attack on Chinese capitalism has been understood. 
Via Talk Markets
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49... 
Via Benzinga
Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer
Bristol Myers Squibb & Co (NYSE: BMY) on Friday said it's voluntarily withdrawing Opdivo's approval in hepatocellular carcinoma (HCC) patients who... 
Via Benzinga
Benzinga's Bulls And Bears Of The Week: Amazon, Apple, Bitcoin, GameStop, Netflix And More
Benzinga has examined the prospects for many investor favorite stocks over the pas... 
Via Benzinga
Healthcare ETFs in Focus as Q2 Earnings Unfold
Let’s dig deeper into the earnings picture of the companies which will drive the performance of healthcare funds in the coming days. 
Via Talk Markets
Why This Trader Expects Bristol-Myers Squibb Stock To Break Out And Trend Higher
Bristol-Myers Squibb Company (NYSE:BMY) is breaking out and p... 
Via Benzinga
2 Dirt Cheap Dividend Stocks You Can Buy Right Now
They may not remain cheap for much longer. 
Via The Motley Fool
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Got $5,000? Here Are 2 Cheap Warren Buffett Stocks to Buy
The stocks come pre-vetted by the best in the business. 
Via The Motley Fool
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
Delta Defeats Bulls
Stocks tended to crash without rhyme or reason. 
Via Talk Markets
Here's Why Cytokinetics Is Rocketing Higher Today
The company's new heart drug candidate produced encouraging clinical trial results. 
Via The Motley Fool
How Strong Cytokinetics Test Results Could Undermine Bristol Myers' $13.1 Billion Buyout
Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted. 
Via Investor's Business Daily
Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial
Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed... 
Via Benzinga
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing Bristol-Myers Squibb's Unusual Options Activity
Shares of Bristol-Myers Squibb (NYSE:BMY) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $67.42. Sentiment:... 
Via Benzinga
XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences
XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ:... 
Via Benzinga
Dialing For Stocks
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Selloff Round 3
Stocks fell across the board in foreign countries, except for Britain which was upbeat. 
Via Talk Markets
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Analyzing Bristol-Myers Squibb's Unusual Options Activity
Shares of Bristol-Myers Squibb (NYSE:BMY) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $67.26. Sentiment:... 
Via Benzinga
Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?
The battle for market share could come down to which drug has the lesser side effects. 
Via The Motley Fool
Recovery Friday
The big winners this week were Financials. 
Via Talk Markets
Unusual Options Activity Insight: Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) shares experienced unusual options activity on Friday. The stock price moved up to $67.41 following the option alert. Sentiment: BEARISH Option... 
Via Benzinga
Top 5 Stocks To Buy For July 2021
Discussion and analysis on my top five stocks for July 2021: BMY, ENB, HBAN, LMT and PNW. 
Via Talk Markets
After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold
Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in... 
Via Benzinga
Exposures Product Safety
Jim Lebenthal Likes AbbVie Stock At Its Current Price
It's a great time to invest in pharmaceutical companies such as AbbVie Inc (NYSE: 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.